Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Intelligent Bio Solutions ( (INBS) ) has provided an announcement.
On December 15, 2025, Intelligent Bio Solutions Inc. received a deficiency letter from Nasdaq due to its stock price falling below $1.00 for 30 consecutive business days, failing to meet the minimum bid price requirement for continued listing. The company has until June 15, 2026, to regain compliance, and has initiated a 1-for-10 reverse stock split to address this issue, effective December 15, 2025, with trading on a split-adjusted basis starting December 16, 2025.
The most recent analyst rating on (INBS) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
Spark’s Take on INBS Stock
According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance and poor valuation metrics, which are significant concerns. However, positive corporate events, such as new customer acquisitions and strategic FDA clearance plans, provide some optimism for future growth. The technical analysis suggests a bearish trend, further weighing down the score.
To see Spark’s full report on INBS stock, click here.
More about Intelligent Bio Solutions
Average Trading Volume: 297,027
Technical Sentiment Signal: Sell
Current Market Cap: $5.34M
See more insights into INBS stock on TipRanks’ Stock Analysis page.